Cindy Boer

154 | Chapter 3.2 Supplementary References 1. Ikram, M.A., et al., Objectives, design and main findings until 2020 from the Rotterdam Study. Eur J Epidemiol, 2020. 35(5): p. 483-517. 2. Teichert, M., et al., A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet, 2009. 18(19): p. 3758-68. 3. Fries, J.F., P.W. Spitz, and D.Y. Young, The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol, 1982. 9(5): p. 789-93. 4. Odding, E., et al., Association of locomotor complaints and disability in the Rotterdam study. Ann Rheum Dis, 1995. 54(9): p. 721-5. 5. Burger, H., et al., The association between age and bone mineral density in men and women aged 55 years and over: the Rotterdam Study. Bone Miner, 1994. 25(1): p. 1-13. 6. Rieder, M.J., et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005. 352(22): p. 2285-93.